Nanosonics (ASX:NAN) advanced the staged rollout of its CORIS system by submitting a second application to the US food and drug administration aimed at broadening approved endoscope indications following its earlier clearance, according to a Tuesday filing with the Australian bourse

The company is also progressing its controlled market release (CMR) program, having installed its first CORIS unit in Australia and started staff training in preparation for a planned rollout, per the filing.

The United Kingdom CMR is ongoing and performing as expected, with Australia and Ireland sites rolling out next and US activities to follow based on early learnings, the filing added.